AlphaCentric Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
AlphaCentric Advisors's NBIX Position: Q3 2026 in Review
AlphaCentric Advisors increased its Neurocrine Biosciences (NBIX) stake by 5.2% in Q3 2026, buying an estimated $80.9K and bringing the position to 10,230 shares worth $1.45M. The position accounts for 1.29% of the portfolio, ranked #11.
AlphaCentric Advisors first reported a position in NBIX in Q2 2020 and has held it in 15 quarters since. The position peaked at $3.44M in Q2 2023. 770 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- AlphaCentric Advisors held 10,230 shares of Neurocrine Biosciences worth $1.45M as of Q3 2026.
- AlphaCentric Advisors bought 503 Neurocrine Biosciences shares in Q3 2026, an estimated $80.9K.
- Neurocrine Biosciences made up 1.29% of AlphaCentric Advisors's portfolio in Q3 2026, its #11 holding.
- AlphaCentric Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 15 quarters since.
- AlphaCentric Advisors's Neurocrine Biosciences position peaked at $3.44M in Q2 2023.
- 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.